Table 5. The four studies selected for examining the association between EGFR mutations and overall survival of NSCLC patients with subsequent brain metastasis.
| Author | Patient EGFRM |
Patient EGFRW |
Medium OS EGFRM | Medium OS EGFRW | Hazard ratio | Exon 19 vs. Other mutation and wild type (HR) |
|---|---|---|---|---|---|---|
| Karmen Stanic [21]* | 26 | 64 | N/A | N/A | N/A (p = 0.7) | N/A |
| Guang Han [51]* | 48 | 28 | 23.8 | 14.2 | N/A (p = 0.028) | N/A |
| Min Young Baek [50] | 7 | 13 | 14.5 | 2.5 | N/A (p = 0.23) | N/A |
| Current study | 49 | 28 | 17.8 | 12.2 | 0.687 (p = 0.30) |
0.58 (p = 0.089) |
*EGFR mutation was an independent prognosis factor under univariate and multivariate analysis.